The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I dose-escalation study to evaluate the safety, pharmacokinetics, and pharmacodynamics of CEP-9722 (a PARP1-2 inhibitor) as single‑agent and in combination with temozolomide in patients with advanced solid tumors (NCT00920595).
Mario Campone
No relevant relationships to disclose
Ruth Plummer
No relevant relationships to disclose
Peter Stephens
No relevant relationships to disclose
Zahir Brakchi
Employment or Leadership Position - Cephalon
Louiza Aissat-Daudigny
Employment or Leadership Position - Cephalon
Fabrice Kasiborski
Employment or Leadership Position - Cephalon
Anne Cambois
Employment or Leadership Position - Cephalon
Gilbert Moachon
Employment or Leadership Position - Cephalon
Peter D. Brown
Employment or Leadership Position - Cephalon
Stock Ownership - Cephalon
Louis Kayitalire
Employment or Leadership Position - Cephalon